About this Research Topic
Immunotherapy biologics have ushered in a new era of treating cancer and infections by leveraging biological agents to amplify the immune response. Using monoclonal antibodies to target specific proteins on pathogens or the tumor markers, these therapies have dramatically shifted treatment paradigms. Biologics such as Bispecific T-cell Engagers facilitate direct T-cell mediated attack by bridging them with target cells, enhancing their efficacy. Similarly, CAR-T cell therapy, involves engineering T-cells to recognize and eliminate disease cells effectively. Moreover, cytokines and monoclonal antibodies play roles in direct neutralization or immune modulation. Despite their success, challenges remain, particularly in treating solid tumors, due to issues like target specificity, therapy endurance, and immunosuppressive environments.
The aim of this Research Topic is to deepen the comprehension of emerging biologics and innovative technologies that can address the multifaceted challenges of using biologics in oncological and infectious disease contexts. The goal is to illustrate the latest advancements and multidisciplinary strategies in the field, enhancing or even replacing current treatments.
The scope of this research topic focuses on overcoming scientific and logistical hurdles that limit current biologic therapies. Articles are to be rigorous and innovative, and should explore one of the following themes:
o Engaging innate and/or adaptive immune responses through novel biologic agents.
o Strategies for targeted biologic delivery to minimize side effects.
o New methods for biologics administration, such as using nucleic acids, lipid nanoparticle systems, or viral vectors.
o Improvements in the fabrication of autologous cell therapies.
o Combining therapies to sidestep or break therapeutic resistance.
o Addressing challenges in antimicrobial resistance through innovative biologic modalities.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
The aim of this Research Topic is to deepen the comprehension of emerging biologics and innovative technologies that can address the multifaceted challenges of using biologics in oncological and infectious disease contexts. The goal is to illustrate the latest advancements and multidisciplinary strategies in the field, enhancing or even replacing current treatments.
The scope of this research topic focuses on overcoming scientific and logistical hurdles that limit current biologic therapies. Articles are to be rigorous and innovative, and should explore one of the following themes:
o Engaging innate and/or adaptive immune responses through novel biologic agents.
o Strategies for targeted biologic delivery to minimize side effects.
o New methods for biologics administration, such as using nucleic acids, lipid nanoparticle systems, or viral vectors.
o Improvements in the fabrication of autologous cell therapies.
o Combining therapies to sidestep or break therapeutic resistance.
o Addressing challenges in antimicrobial resistance through innovative biologic modalities.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords: Biologics, Adaptive Immunity, Cancer Infectious Disease Immunotherapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
